1. Introduction {#s0005}
===============

Struma ovarii is a specialized or monodermal teratoma predominantly composed of mature thyroid tissue, and its malignant counterpart has thyroid cancer components. Malignant struma ovarii (MSO) presenting with follicular-type carcinoma is extremely rare. Most MSO lesions histologically appear as papillary carcinoma; approximately 50 cases of MSO with follicular-type carcinoma have been reported in the English literature ([Table 1](#t0005){ref-type="table"}). Recently, driver gene alterations of thyroid cancer have been elucidated, and a few reports showed that MSO presenting with papillary carcinomas harbored *BRAF* or *RAS* gene mutations ([@bb0015]; [@bb0040]) that are frequently observed in papillary thyroid carcinoma ([@bb0005]). However, MSO with follicular carcinoma (MSOFC) has not been assessed for known major molecular alterations in follicular thyroid carcinoma such as *RAS* gene mutations and *PPARg-PAX8* fusion ([@bb0025]; [@bb0045]).Table 1Previously reported cases of malignant struma ovarii with follicular carcinoma.Table 1\#First authorYearAgeExtraovarian spreadTreatment of extraovarian diseasePrognosis and follow-up1De Graaff198372Peritoneal disseminationOmentectomyNED, 3 yrs2Willemse198736Peritoneal disseminationRAIRec, 4 mo3O\'Connell199035NoNoneNED4Zakhem C1199052NoNoneNED, 1.7 yrs5Zakhem C2199030NoNoneNED, 2.7 yrs6Kragel199137Peritoneal disseminationNoneNED, 5 yrs7Thomas C1199217Peritoneal disseminationRAINED, 2 yrs8Thomas C2199235Peritoneal disseminationOmentectomyNA9Ito199236Bone metastasisChemotherapyNED, 1 mo10Balasch199336Peritoneal disseminationRAI to be consideredNA11Ayhan199366Peritoneal disseminationOmentectomyAWD, 8 yrs12Tokuda199325Cranial metastasisResectionNED13Karseladze199449Peritoneal disseminationChemotherapyNED, 16.3 yrs14Piana199426NoNoneNED 1 yr15Brenner199649Urinary bladder metastsisRAINED, 3.2 yrs16Tennvall C1199750Peritoneal disseminationOmentectomy, RAINED, 6 yrs17Tennvall C2199743Peritoneal disseminationNoneDied(GBC), 4 mo18Mango199747Pelvic bone metastasisRAIAWD, 4 mo19Barrande199731NoRAINED, 6 mo20Bhansali199947NoRadiationNED, 4 yrs21Takeuchi C1200043Peritoneal disseminationOmentectomyNED, 7 yrs22Takeuchi C2200070Peritoneal disseminationOmentectomy, PLNDNED, 2 yrs23Rotman-Pikielny200046Liver metastasisRAIAWD, 6 mo24Konez200045Liver metastasisRAINA25Chan200127Bone metastasisRAIAWD, 8 mo26Checrallah200138Lung and bone metastasisRAIAWD, 6 yrs27DeSimone200332NoRAINED, 1.2 yrs28Kdous200345NoNoneNED, 1 yr29Brogsitter200450Peritoneal disseminationRAINED, 6 mo30Ihalagama200427Pritoneal cyology positiveRAINED 1.5 yrs31Garcia200522Invasion to adjucent tissueResectionNED, 6 yrs32McDougall200617Liver and bone metastasisRAIAWD, 4 yrs33Zekri200626Lung and bone metastasisRAIAWD, 15 yrs34Roth, C1200832Peritoneal disseminationRAIRec, 26 yrs35Roth, C2200849Peritoneal disseminationChemotherapyNED, 16.3 yrs36Roth, C3200850Peritoneal disseminationResection & RAINED, 6 yrs37Roth, C4200870Peritoneal disseminationRAIDOD, 3 yrs38Prasad200840Pelvic massResection & RAINED, 4 yrs39Kim200949Peritoneal disseminationOmentectomyNA40Michels201041Peritoneal disseminationRAIAWD, 3 mo41Selvaggi201250Peritoneal disseminationOmentectomyNED, 1 yr42Shirimali, C1201252Vaginal vault massRAINA43Shirimali, C2201259Peritoneal disseminationRAINA44Shirimali, C3201253Peritoneal disseminationRAINA45Carey201470Peritoneal disseminationRAINA46Ukita201445Lung and bone metastasisChemotherapyAWD, 20 yrs47Cong201538Lung metastasisRAIAWD, 3 yrs48Kobayashi201549Spinal metastasisRadiationAWD, 9 mo49Ranade201555Peritoneal disseminationRAIAWD, 3 mo50Park201535Peritoneal disseminationRAINED, 25 mo51Anagnostou201664Peritoneal disseminationOmentectomyNED, 4 yrs52Riggs201832Peritoneal disseminationLaparoscopic resectionNED, 1 yr53*Present case*201939Peritoneal disseminationResection & RAIAWD, 2 yrs[^1][^2]

The histological diagnosis of MSOFC is often challenging, because it is frequently impossible to evaluate capsular invasion in the ovary. In these cases, a diagnosis of MSOFC is based on the evidence of malignant behaviors such as the presence of vascular invasion, dissemination, or metastasis. Therefore, the identification of a specific molecular alteration in MSOFC can be a useful biomarker for the prediction of malignant behavior of MSOFC even when confined to the ovary.

Herein, we report a case of MSOFC presenting with peritoneal dissemination for which we performed molecular analysis including DNA sequencing, immunohistochemistry, and fluorescent in situ hybridization (FISH) for major pathogenic molecular alterations in thyroid follicular carcinoma. To the best of our knowledge, this is the first report of MSOFC with detailed molecular analysis.

2. Case presentation {#s0010}
====================

A 39-year-old nulliparous woman was referred with a diagnosis of highly differentiated follicular carcinoma of ovarian origin (HDFCO). She underwent left salpingo-oophorectomy for mature cystic teratoma with thyroid tissue in the left ovary 16 years ago and cystectomy for right struma ovarii 8 years ago. Two years ago, an approximately 4 cm wide ovarian mass was detected that had increased in diameter up to 7 cm. Furthermore, other new lesions were found in the pelvic cavity. These lesions were surgically resected and histologically diagnosed as peritoneal dissemination of HDFCO. She had no primary thyroid cancer, and thyroid function test results (serum T3, T4, and TSH) were normal. At our hospital, ^123^I scintigraphy revealed multiple lesions in the abdominopelvic cavity and she underwent an abdominal hysterectomy, right salpingo-oophorectomy, and partial omentectomy for residual tumors. All macroscopic tumors were removed. She was discharged without any complications. Although no macroscopic residual disease was found intraoperatively, intraperitoneal microscopic residual disease was detected via ^123^I scintigraphy performed 6 weeks after the surgery. Additional radioactive iodine therapy (RAI) was planned for the residual disease, and total thyroidectomy was performed in preparation for RAI. Pathological examination revealed an adenomatous goiter without any malignant features. Two months after thyroidectomy, RAI was initiated. After completing 4 cycles of RAI, the patient has been alive with residual disease for 2 years after the gynecologic surgery.

2.1. Pathological findings {#s0015}
--------------------------

Macroscopically, there were multiple tan-colored solid tumors on the omentum ([Fig. 1](#f0005){ref-type="fig"}A and B), and the largest mass was 4 × 3 × 2.5 cm in size. Microscopically, there were many follicles of various sizes composed of tumor cells without nuclear features of papillary thyroid carcinoma such as overlapping nuclei, irregular contours, nuclear grooves, pseudo inclusions, and chromatin clearing. Microscopic lesions were also found in the right ovary and on the uterine serosa. No carcinoid component was observed. Tumor cells showed mild nuclear atypia and formed numerous micro- to normal-sized follicles, resembling a thyroid follicular tumor rather than non-neoplastic thyroid tissue. Immunohistochemically, tumor cells showed diffuse positivity for TTF-1 and PAX8 ([Fig. 1](#f0005){ref-type="fig"}E and F). The final pathological diagnosis was peritoneal dissemination of MSOFC.Fig. 1Malignant struma ovarii presenting with follicular carcinoma. (A) There are multiple tumor nodules on the omentum. (B) The cut surface of the tumor is tan-colored and solid. (C) At low magnification, there are follicles of various sizes containing pink-colored colloid resembling thyroid follicular tumor. (D) At higher magnification, no nuclear features suggesting papillary carcinoma, nuclear groove, ground-glass appearance, and intranuclear cytoplasmic inclusion are observed. Immunohistochemically, tumor cells show diffuse positivity for PAX8 (E) and TTF-1 (F). Scattered p53 positive tumor cells showing a wild-type staining pattern (G). Nuclear accumulation of β-catenin is not observed. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

2.2. Molecular analysis {#s0020}
-----------------------

All molecular analyses were approved by the institutional review board of our hospital. A representative section of an omental lesion was selected for all subsequent analyses. Immunohistochemical analyses for p53, β-catenin, BRAF^V600E^, and PTEN and split FISH assay for *PPARgamma* rearrangement were performed on formalin-fixed paraffin-embedded specimens. Targeted sequencing of 50 cancer-related genes (the Ion Ampliseq™ Cancer Hotspot Panel version 2) was performed using DNA extracted from the resected tumor tissue. All the targeted genes are listed in the supplementary materials and methods. These 50 genes included well-known proto-oncogenes and tumor suppressor genes such as *BRAF*, *EGFR*, *ERBB2*, *HRAS*, *KIT*, *KRAS*, *NRAS*, *PIK3CA*, *PTEN*, *APC*, *CTNNB1*, *RET*, and *TP53*. Details of the methods of molecular analysis mentioned above are provided in the supplementary materials and methods.

The results of these analyses are described below. Immunohistochemically, tumor cells showed scattered positivity for p53, the so-called wild-type pattern ([Fig. 1](#f0005){ref-type="fig"}G). Nuclear accumulation of β-catenin was not observed ([Fig. 1](#f0005){ref-type="fig"}H). The tumor cells tested negative for BRAF^V600E^. Split probe FISH assay for PPARgamma showed no split signals in the nuclei of tumor cells ([Fig. 2](#f0010){ref-type="fig"}). Target sequencing revealed no pathogenic/oncogenic mutations in the 50 cancer-related genes, including *BRAF*, *EGFR*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *CTNNB1*, and *TP53*.Fig. 2Split probe fluorescence in situ hybridization assay for *PPAR-gamma* gene rearrangement. Red signal (distal gene region) and green signal (proximal gene region) were not split in the nuclei of tumor cells. The black and white arrowheads indicate red and green signals, respectively (inset). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

3. Discussion {#s0025}
=============

We, herein, reported a rare case of MSOFC presenting with peritoneal dissemination for which we performed a molecular analysis. The major known driver gene alterations in follicular thyroid carcinoma were not detected, which implied the possibility of a different mechanism of tumorigenesis for MSOFC.

MSOFC is extremely rare, and about 50 cases have been reported, including HDFCO (the so-called peritoneal strumosis) and MSO with typical follicular carcinoma ([Table 1](#t0005){ref-type="table"}). To date, there has been only one case of death due to this tumor with a poorly differentiated follicular carcinoma component ([@bb0030]). Most cases did not show dismal prognoses; however, the long-span of recurrent disease deteriorates the quality of patients\' lives.

Making a diagnosis of MSOFC is challenging, especially for cases confined to the ovaries, and histomorphological features play a limited role in predicting subsequent malignant behavior. The present case was diagnosed as mature teratoma with thyroid tissue 16 years ago and the same tumor cells formed multiple lesions in the right ovary 8 years ago, on the peritoneum, and omentum 2 years ago. Unless peritoneal dissemination, evidence of malignant behavior, was detected, a diagnosis of MSOFC could not be rendered. This is because the tumor confined to the ovary showed no histological evidence of malignancy such as vascular invasion. Therefore, any specific molecular abnormalities in MSOFC would become useful biomarkers for predicting peritoneal dissemination or metastasis.

Driver gene mutations of thyroid cancer have been well investigated, and a correlation with histological subtypes has also been reported ([@bb0005]; [@bb0025]; [@bb0045]). The majority of papillary thyroid cancers are reported to have *BRAF*^*V600E*^, *RAS*, and *RET* genetic alterations, which are most often mutually exclusive ([@bb0005]). Moreover, follicular thyroid cancers harboring either *RAS* mutations or *PAX8/PPARG* gene fusion comprise approximately 80% of cases ([@bb0010]). Furthermore, less differentiated carcinomas, such as anaplastic carcinomas, have been reported to harbor *p53* mutations or abnormalities in β-catenin signaling. The phosphatidylinositide 3-kinase (PI3K)/AKT pathway is also affected and can occur by activating mutations in *PIK3CA* or *AKT1*, or loss of *PTEN*. A few reports showed that *BRAF* mutations frequently occur in MSO with papillary carcinoma but not benign tumors ([@bb0035]), and *RAS* mutations were reported in MSO with follicular variants of papillary carcinoma ([@bb0040]). These authors postulated that MSO with papillary carcinoma might share a mechanism of carcinogenesis with papillary thyroid carcinoma. Recently, Park et al. first reported a case of MSOFC without mutation of *BRAF*^*V600E*^, *RAS* (*HRAS* codon 61, *NRAS* codon 61, and *KRAS* codon 12/13), and *PAX8/PPARG* gene fusion ([@bb0020]). Unfortunately, detailed materials and methods of the analysis are not given in the article. In line with this previous report, we did not detect any major molecular alterations in this case, regardless of more extensive analyses, including mutation analyses of 50 cancer-related genes. These negative findings may suggest different mechanisms of tumorigenesis in MSOFC. Interestingly, infrequent *RAS* mutations and *PPARgamma* rearrangement is reported as a unique feature of pediatric follicular thyroid carcinoma. Vuong et al. reported that only 12.2% (5/41) of *NRAS* mutations and no *PPARgamma* rearrangements occurred in 41 pediatric cases of follicular thyroid carcinoma ([@bb0050]). We, therefore, speculate that MSOFC is a type of malignant transformation of monodermal teratoma and may be similar to pediatric follicular thyroid carcinoma rather than the adult-type.

Since we investigated only one case and analyzed a limited number of gene alterations, a strong conclusion could not be drawn. We expect that our findings will be validated in another cohort of MSOFC cases and evoke additional analyses. The identification of new driver gene alterations may require more extensive investigations such as whole-exome sequencing.

Summarily, we described a case of MSOFC without the major pathogenic molecular alterations of adult-type follicular thyroid cancer. These results imply the possibility of a different tumorigenesis pathway of MSOFC from that of thyroid follicular carcinoma. Further studies are needed to identify biomarkers for predicting malignant behavior.
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[^1]: Abbreviations; RAI, radioactive iodine therapy; NED, no evidence of disease; Rec, recurrence; NA, not available; AWD, alive with disease; GBC, gallbladder cancer; DOD, death of disease; C\# denotes case\# in the same report; PLND, pelvic lymph node dissection.

[^2]: The complete list of all the reference above is provided as Supplementary material.
